- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04727411
Analysis of Conjunctival Changes as Indicators for Ab-interno Gelatin Microstent Implantation Surgery Outcomes (IIT_XEN)
In Vivo Imaging and Impression Cytology Analysis of Conjunctival Changes as Potential Indicators for Ab-interno Gelatin Microstent Implantation Surgery Outcomes
Trabeculectomy and XEN45 gel stent implantation are glaucoma surgeries that creates an aqueous humor (AH) shunt towards the subconjunctival space (filtration bleb). Once the AH reaches the subconjunctival space, it is removed by different paths such as the trans-bleb wall route. For this reason, the conjunctiva is considered an essential structure that may condition the glaucoma filtering procedures outcomes. As part of the inflammatory response, an unbalanced fibrosis during the postoperative period may lead to a bleb cavity scarring and failure; for this reason, bleb massage and antifibrotic injections (i.e., 5-Fluoruracil) are frequently required as part of the postoperative care of these procedures. There have been described several risk factors, such as intraocular pressure (IOP) lowering medications, previous surgical interventions or ocular surface disease that may predispose to an early failure. These preoperative factors fail to aim to predict the surgical outcomes.
However, ocular biomarkers may overcome this limitation. There are promising studies that have analyzed the role of in vivo confocal microscopy (IVCM), anterior-segment optical coherence tomography (AS-OCT) and conjunctival cytology impression as clinical tools that may improve the filtration bleb assessment at a cellular level.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Detailed description Hypothesis
- Conjunctival biomarkers may represent a predictive factor to determine the XEN45 and trabeculectomy surgical success and outcomes
- A cellular-based analysis may help to predict postoperative pro-fibrotic changes that may lead to an early or mid-term surgery failure, and therefore it could help to improve the postoperative care of the filtering bleb.
Objective
- To evaluate the preoperative and postoperative conjunctival factors that may influence in the surgical outcomes of XEN45 gel stent compared to trabeculectomy using in vivo confocal microscopy, anterior segment optical coherence tomography and conjunctival cytology impression
- To assess the efficacy of XEN Gel stent and trabeculectomy to predict IOP, based on the morphologic characteristics of the filtering bleb
- To analyze the needling rate during the postoperative bleb management and the potential correlation to the pre and postoperative conjunctival changes and surgical success outcomes
Design Single-center, prospective, simple-blind study
Primary outcomes All the outcomes are measured pre and postoperative at each follow-up time
- In vivo confocal microscopy images: goblet cells density, dendritic cell density and stromal fibrosis
- Anterior segment optical coherence tomography: wall thickness and epithelium thickness
- Conjunctival cytology impression: dendritic cells, goblet cells
Secondary outcomes
- Intraocular pressure
- Number of IOP lowering medications
- Number of postoperative needling
Sample size calculation Based on the most assessed outcome in glaucoma surgeries and the only pilot study aiming to determine a similar outcome, to detect IOP differences between both procedures that may reflect the surgical outcomes of both procedures and therefore reflect the subconjunctival changes, accepting an alfa risk of 0.05 and a beta risk of 0.20 in a two-sided Student's T-test, 40 subjects are necessary in each group to recognize as statistically significant a difference greater than or equal to - 13,38 mm Hg in IOP, with a common standard deviation of 17%. A drop-out rate of 15% has been anticipated. If no drop-out rate is considered, the number of needed subjects is 68 (34 per group)
Method Single center, prospective, observational study of primary open angle glaucoma and uncontrolled intraocular pressure, progression of the disease confirmed by visual field examination that require either XEN gel stent implantation or trabeculectomy.
Preoperative examinations
- Medial records including ophthalmic procedures, other ocular diseases, intraocular pressure while on treatment, target pressure, visual field, detailed description of the optic disc, both preoperative and postoperative
- Glaucoma staging: peripapillary retinal nerve fiber layer, visual field (baseline, 3 moths and 6 months)
Ocular biomarkers
- In vivo confocal microscopy (baseline, 3 moths and 6 months)
- Conjunctival impression cytology (baseline, 3 moths and 6 months)
A specific case report form (CRF) was designed with all variables and data required for the study, including potential complications
Surgery. Patients were assigned either to trabeculectomy or XEN stent implantation
Trabeculectomy: the surgical technique is as follows: retro/peribulbar o subtenon's anesthesia, superior corneal traction suture, phacoemulsification through 2.2 with in-the-bag IOL implantation, a fornix-based conjunctival flap, sufficient but not excessive cauterization, application mitomycin-C (MMC) 0,2 mg/ml for 2 minutes under the conjunctiva, then MMC was washed out with 100 ml of saline solution, then a scleral flap (4x3 mm in the trabeculectomy) is dissected. A sclerectomy with punch and peripheral iridectomy were performed, and suture nylon 10/00 sutures was used to place 3 or 4 stiches in the scleral flap
XEN gel stent: a clear cornea incision in the inferotemporal quadrant was performed, injecting the XEN 45 device into the superonasal quadrant using an ab interno approach. Approximately 15 min before inserting the implant, 0.1 ml of a MMC solution (0.01%) was injected into the superior conjunctiva. Both stand-alone and combined phaco-glaucoma procedures were used.
Post-operative treatment. All patients instilled ofloxacin antibiotic every 6 hours for 1 week, dexamethasone (every 2 hours for 1 month, every 4-6 hours on the second month and tapered during the third month according to surgeon's instructions). Atropine was also used when clinical finds recommended its use. Subconjunctival injections of anti-fibrotic agents (5-FU) and/or bleb needling were allowed and performed at the discretion of the surgeon
Statistical analysis
- Descriptive statistics, including mean and standard deviation for normally distributed variables and median and interquartile range for non-normally distributed variables, previous checked using Shapiro-Wilk test.
- Logistic regression models to evaluate the correlation with preoperative and postoperative factors and needling rate, surgical success (IOP < 18 mm Hg), and ocular biomarkers. The results will be reported as odds ratio (OR).
- All the reported values will be considered statistically significant at two-tailed p <0.05
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08028
- Hospital Clínic - ICOF
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Primary open angle glaucoma
- Written informed consent
- Older than 18 years old
Exclusion Criteria:
- Patients that don't fully understand the purpose and the postoperative care
- Severe or end-stage glaucoma
- Patients with prior ocular surgery, excluding uncomplicated phacoemulsification 6 months prior to the inclusion in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Gel Stent implantation
XEN gel stent: a clear cornea incision in the inferotemporal quadrant was performed, injecting the XEN 45 device into the superonasal quadrant using an ab interno approach.
Approximately 15 min before inserting the implant, 0.1 ml of a MMC solution (0.01%) was injected into the superior conjunctiva.
Both stand-alone and combined phaco-glaucoma procedures were used.
|
XEN Gel stent implantation either combined or as a stand-alone procedure
|
Experimental: Trabeculectomy
Trabeculectomy: the surgical technique is as follows: retro/peribulbar o subtenon's anesthesia, superior corneal traction suture, phacoemulsification through 2.2 with in-the-bag IOL implantation, a fornix-based conjunctival flap, sufficient but not excessive cauterization, application MMC 0,2 mg/ml for 2 minutes under the conjunctiva, then MMC was washed out with 100 ml of saline solution, then a scleral flap (4x3 mm in the trabeculectomy) is dissected.
A sclerectomy with punch and peripheral iridectomy were performed, and suture nylon 10/00 sutures was used to place 3 or 4 stiches in the scleral flap
|
XEN Gel stent implantation either combined or as a stand-alone procedure
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
In vivo confocal microscopy of the filtering bleb
Time Frame: Preoperative to 6 months operative
|
Increase of the mean microcysts density (MMD): number of cysts/mm2
|
Preoperative to 6 months operative
|
Anterior segment optical coherence tomography microscopy of the filtering bleb
Time Frame: Preoperative to 6 months operative
|
Differences in thickness of the conjunctival epithelial surface and the bleb wall, in micrometers
|
Preoperative to 6 months operative
|
Conjunctival impression cytology of the filtering bleb
Time Frame: Preoperative to 6 months operative
|
Increase in the percentage of goblet cells biomarkers
|
Preoperative to 6 months operative
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intraocular pressure
Time Frame: Preoperative to 6 months visit, at each follow-up visit
|
Difference of intraocular pressure, in mm Hg
|
Preoperative to 6 months visit, at each follow-up visit
|
Glaucoma medications
Time Frame: Preoperative to 6 months visit, at each follow-up visit
|
Difference between the number of glaucoma medications before and after each surgery
|
Preoperative to 6 months visit, at each follow-up visit
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marta Pazos, MD, PhD, Hospital Clinic
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HCB/2019/0035
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glaucoma
-
Imperial College Healthcare NHS TrustIRIDEX CorporationNot yet recruitingGlaucoma | Glaucoma, Open-Angle | Glaucoma, Angle-Closure | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma Secondary | Glaucoma Traumatic | Glaucoma Uveitic
-
Wills EyeIOP OphthalmicsTerminatedPrimary Open Angle Glaucoma | Neovascular Glaucoma | Uveitic Glaucoma | Pseudoexfoliation Glaucoma | Primary Angle Closure Glaucoma | Pigmentary Glaucoma | Traumatic GlaucomaUnited States
-
Centre hospitalier de l'Université de Montréal...CompletedGlaucoma | Glaucoma, Open-Angle | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma and Ocular Hypertension | Glaucoma, Uncompensated | Glaucoma SecondaryCanada
-
Pro Top & Mediking Company LimitedCompletedOpen Angle Glaucoma | Neovascular Glaucoma | Angle Closure Glaucoma | Uveitis Glaucoma | Young Age Glaucoma | High Risk PatientEstonia
-
Sanoculis LtdCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaIsrael
-
Bausch & Lomb IncorporatedNicOx Inc.CompletedPrimary Open Angle Glaucoma | Ocular Hypertension | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
Sensimed AGCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaFrance
-
Wills EyeOptovueCompletedPrimary Open-angle Glaucoma | Normal Tension Glaucoma | Glaucoma; DrugsUnited States
-
Ivantis, Inc.CompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
University of California, San FranciscoUniversity of Colorado, Denver; University of Maryland; Zhongshan Ophthalmic... and other collaboratorsCompletedPrimary Open Angle Glaucoma | Glaucoma | Neovascular Glaucoma | Secondary GlaucomaUnited States, China, India, Mexico
Clinical Trials on XEN45 Gel stent
-
Trakya UniversityCompleted
-
AbbVieRecruiting
-
AqueSys, Inc.CompletedPrimary Open Angle GlaucomaSpain, Austria, Belgium, Italy, Germany, Poland, Switzerland, United Kingdom, Venezuela
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityAllerganActive, not recruitingGlaucoma | Glaucoma, Open-Angle | SurgeryChina
-
AllerganCompletedGlaucoma | Angle-ClosureAustralia, Canada, Korea, Republic of, Singapore, Taiwan, United Kingdom
-
Swiss Vision NetworkActive, not recruitingGlaucoma | Glaucoma, Open-Angle | Glaucoma, Angle-Closure | Glaucoma, Primary Open Angle
-
Johns Hopkins UniversityNew York UniversityCompletedGlaucoma, Open-AngleUnited States
-
Paracelsus Medical UniversityCompletedGlaucoma | Endothelial Cell Loss, CornealAustria
-
Cairo UniversityRecruitingFree Gingival GraftEgypt
-
AllerganCompleted